Skip to main content

Table 1 Patient characteristics of the study population in the primary analysis

From: Impact of the interval between neoadjuvant concurrent chemoradiotherapy and esophagectomy in the modern era: a population-based propensity-score-matched retrospective cohort study in Asia

 

Unmatched population

 

Matched study population

 

Short interval (n = 169)

Long interval (n = 87)

Short interval (n = 80)

Long interval (n = 80)

Number or

mean (sd)

(%)

Number or

mean (sd)

(%)

SDif

Number or

mean (sd)

(%)

Number or

mean (sd)

(%)

SDif

Age

 

54.71 (8.53)

 

53.21 (8.30)

 

0.179

53.48 (8.62)

 

52.94 (8.31)

 

0.063

Gender

Female

13

(8)

5

(6)

0.078

5

(6)

5

(6)

0

Male

156

(92)

82

(94)

 

75

(94)

75

(94)

 

Residency

Non-north

110

(65)

46

(53)

0.250

46

(57)

45

(56)

0.025

North

59

(35)

41

(47)

 

34

(43)

35

(44)

 

Tumor size

≤ 5 cm

61

(36)

43

(49)

0.272

35

(44)

37

(46)

0.050

> 5 cm

108

(64)

44

(51)

 

45

(56)

43

(54)

 

Tumor differentiation

Poorly/undifferentiated

66

(39)

15

(17)

0.500

15

(19)

15

(19)

0

Well/moderately

103

(61)

72

(83)

 

65

(81)

65

(81)

 

RT delivery

Non-IGRT

145

(86)

62

(71)

0.360

62

(77)

60

(75)

0.059

IGRT

24

(14)

25

(29)

 

18

(23)

20

(25)

 

Use of PET

No

14

(8)

7

(8)

0.009

5

(6)

7

(9)

0.095

Yes

155

(92)

80

(92)

 

75

(94)

73

(91)

 

Tumor location

Cervical

0.220

0

Non-cervical

 

 

T-stage

T1–T2

21

(12)

10

(11)

0.029

10

(13)

10

(13)

0

T3–T4

148

(88)

77

(89)

 

70

(87)

70

(87)

 

N-stage

Negative

20

(12)

8

(9)

0.086

14

(18)

8

(10)

0.219

Positive

149

(88)

79

(91)

 

66

(82)

72

(90)

 

Drinking

No

23

(14)

7

(8)

0.180

8

(10)

7

(9)

0.043

Yes

146

(86)

80

(92)

 

72

(90)

73

(91)

 

Betel nut chewing

No

75

(44)

30

(34)

0.204

29

(36)

28

(35)

0.026

Yes

94

(56)

57

(66)

 

51

(64)

52

(65)

 

Smoking

No

24

(14)

10

(11)

0.081

10

(13)

10

(13)

0

Yes

145

(86)

77

(89)

 

70

(87)

70

(87)

 

BMI

 

22.08 (3.34)

 

22.69 (4.62)

 

0.152

21.91 (3.35)

 

22.39 (3.32)

 

0.146

Number of lymph nodes

< 15

33

(20)

17

(20)

0

20

(25)

16

(20)

0.120

≥ 15

136

(80)

70

(80)

 

60

(75)

64

(80)

 

RT dose (Gy)

 

48.30 (3.30)

 

46.80 (4.06)

 

0.405

47.51 (3.59)

 

47.16 (3.92)

 

0.094

  1. BMI body mass index, IGRT image-guided radiotherapy, nCCRT neoadjuvant concurrent chemoradiotherapy, PET positron emission tomography, RT radiotherapy, sd standard deviation, SDif standardized difference
  2. Rounded
  3. The exact numbers were not reported because of a Health and Welfare Data Science Center (HWDC) database center policy to avoid numbers in single cells (≤ 2)